Agenus (NASDAQ:AGEN) Given “Neutral” Rating at HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports.

Agenus Price Performance

NASDAQ:AGEN opened at $2.05 on Wednesday. The firm has a market capitalization of $48.09 million, a price-to-earnings ratio of -0.18 and a beta of 1.23. The business has a fifty day moving average price of $3.24 and a 200-day moving average price of $3.85. Agenus has a one year low of $1.93 and a one year high of $19.69.

Agenus (NASDAQ:AGEN) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. On average, equities research analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its stake in shares of Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 51,566 shares during the last quarter. Corton Capital Inc. purchased a new position in shares of Agenus in the fourth quarter valued at approximately $36,000. Bank of America Corp DE lifted its stake in shares of Agenus by 34.0% in the fourth quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock worth $294,000 after buying an additional 27,157 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Agenus by 97.6% during the 4th quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 52,215 shares during the last quarter. Finally, B. Riley Financial Inc. purchased a new stake in Agenus in the 4th quarter valued at $2,074,000. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.